The new Interferon-free, all-oral, three direct-acting-antiviral ( 3D ) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus ( HCV ) genotype 1 ( GT1 ); according to the results of three studies presented today at the International Liver Congress 2014.
The 3D regimen consists of the HCV NS3/4A protease inhibitor ABT-450 dosed with Ritonavir, the NS5A inhibitor ABT-267, and the NS5B RNA polymerase inhibitor ABT-333.
In the SAPPHIRE-I study, treatment naïve patients with chronic HCV GT1 infection and no evidence of liver cirrhosis, were given 12 weeks of treatment with the 3D regimen plus Ribavirin ( RBV ). After 12 weeks, the overall intention-to-treat SVR12 rate was 96.2%. Even in the more difficult-to-treat subtype GT1a, which made up the majority of patients in this study, the SVR12 rate was 95.3% compared to 98% in GT1b patients.
The results from TURQUOISE-II trial have demonstrated the efficacy of the 3D regimen even in HCV GT1a and GT1b patients with cirrhosis.
Using an intention-to-treat analysis, in the 12 weeks treatment arm 91.8% of patients achieved SVR12; in the 24 weeks treatment arm, 95.9% of patients achieved SVR12.
Finally, a third study, PEARL-III, studying the efficacy and tolerability of investigational 3D regimen in treatment naïve adults with chronic genotype 1b ( GT1b ), and no evidence of liver cirrhosis, were randomised to receive the 3D regimen with or without Ribavirin. Following 12 weeks of treatment, 99.0% receiving the regimen without Ribavirin and 99.5% receiving the regimen with Ribavirin achieved SVR12.
Study 1: SAPPHIRE I: phase 3 placebo-controlled study of Interferon-free, 12-week regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin in 631 treatment-naïve adults with hepatitis C virus genotype 1
Ninety-six percent SVR12 achieved in treatment naïve HCV genotype 1 patients on investigational all-oral, Interferon-free, 12-week regimen.
In the 631-patient SAPPHIRE-I study, treatment-naïve patients chronically infected with HCV GT1, were treated with the 3D regimen plus Ribavirin for 12 weeks. Patients were randomized to active treatment for 12 weeks or to start with a placebo for 12 weeks, followed by active treatment. The intention-to-treat SVR12 rate for the 3D regimen for those initially randomized to the active treatment arm was 96.2% ( n=455/473 ). The final SVR12 results for those randomized to start with the placebo treatment are not yet available.
In the active treatment arm, patients with GT1b infection achieved 98% SVR12 ( 148/151 ), while patients with the more difficult-to-treat subtype GT1a achieved 95.3% SVR12 ( 307/322 ).
In this intent-to-treat analysis, patients with missing values for any reason were considered treatment failures. The rate of virological relapse or breakthrough was low, occurring in only 0.2% of patients during treatment with the 3D regimen and 1.5% of patients as a post-treatment relapse.
During the double-blind period, the most common treatment-emergent adverse events in the 3D and placebo arms were fatigue ( 34.7% and 28.5%, respectively ) and headache ( 33.0% and 26.0%, respectively ); the frequency of these events did not differ between treatment arms ( P=NS ).
Discontinuation rates due to adverse events were low, and an equal percentage ( 0.6% ) in both active and placebo groups.
Study 2: TURQUOISE-II: SVR12 rates of 92-96% in 380 hepatitis C virus genotype 1-infected adults with compensated cirrhosis treated with ABT-450/R/ABT-267 and ABT-333 plus Ribavirin ( 3D + RBN )
TURQUOISE-II trial has demonstrated efficacy of 3D regimen even in HCV GT1 patients with cirrhosis.
From a global study population of 380 GT1a and GT1b, treatment-naive and treatment-experienced patients with compensated cirrhosis: 208 patients were randomised to the 3D regimen with Ribavirin for 12 weeks, and 172 patients randomised to the 3D regimen with Ribavirin for 24 weeks.
Using an intention-to-treat analysis, in the 12 weeks treatment arm 91.8% of patients ( n=191/208 ) has achieved SVR12; in the 24 weeks treatment arm, 95.9% of patients ( n=165/172 ) has achieved SVR12. The difference between the two treatment arms was not statistically significant.
Virological relapse or breakthrough was noted in around 6% of patients in the 12-week arm and around 2% in the 24-week arm.
The three most common adverse events in the 12-week and 24-week treatment arms were respectively fatigue ( 32.7% and 46.5% ), headache ( 27.9% and 30.8% ) and nausea ( 17.8% and 20.3% ).
Discontinuations due to adverse events were noted in approximately 2% of subjects in both treatment arms. The safety profile was consistent with results in non-cirrhotic populations using the 3D with Ribavirin regimen.
Study 3: PEARL-III: 12 weeks of ABT-450/R/267 plus ABT-333 has achieved SVR in greater than 99% of 419 treatment-naïve HCV genotype 1B-infected adults with or without Ribavirin
PEARL-III has demonstrated efficacy of 3D regimen with or without Ribavirin for treatment of HCV GT1b-infected, non-cirrhotic, treatment-naive adults.
This 419-patient studied 3D regimen with or without Ribavirin, in adults with chronic genotype 1b ( GT1b ) who were new to treatment and had no evidence of liver cirrhosis. Following 12 weeks of treatment, 99% receiving the 3D regimen with placebo in place of Ribavirin ( n=207/209 ) and 99.5% receiving the regimen with Ribavirin ( n=209/210 ) has achieved SVR12.
High response rates were observed across all HCV GT1b patients in the study, including those patient populations with those characteristics ( male gender, Black race and IL28B non-CC genotypes ) historically associated with having a decreased response to treatment.
No on-treatment virological failures occurred in the treatment arm without Ribavirin and one single virological failure occurred in the treatment arm with Ribavirin.
Across both treatment arms, there were no documented relapses within 12 weeks post-tretament. ( Xagena )
Source: European Association for the Study of the Liver ( EASL ), 2014